Skip to main content

Table 3 OS according to the frequency of the reported cell populations

From: Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients

Cut-off (median frequency)

Median survival (months) (95% CI)

p value

CD8+ lymphocytes

 < 25.1%

15.4 (5.8–25.0)

0.18

 > 25.1%

6.9 (0.1–13.7)

CD8+ CD73 + lymphocytes

 < 5.8%

17.9 (4.9–30.9)

0.06

 > 5.8%

8.0 (0.8–15.2)

CD8+PD-1+ lymphocytes

 < 9.8%

19.2 (10.1–28.3)

0.008

 > 9.8%

6.0 (0–12.8)

CD8+PD-1+CD73+ lymphocytes

 < 2.3%

22.4 (13.6–31.2)

0.001

 > 2.3%

6.9 (0.8–13.0)